Open AccessGuidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option
Author(s) -
Matthew M Rusgis,
Afaq Y Alabbasi,
Leigh Anne Nelson
Publication year - 2021
Publication title -
american journal of health-system pharmacy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.487
H-Index - 96
eISSN - 1535-2900
pISSN - 1079-2082
DOI - 10.1093/ajhp/zxab065
Subject(s) - cabergoline , aripiprazole , medicine , bromocriptine , antipsychotic , adverse effect , tolerability , discontinuation , pharmacology , prolactin , psychiatry , schizophrenia (object oriented programming) , hormone
This article aims to evaluate management options for antipsychotic-induced hyperprolactinemia and associated treatment considerations such as efficacy, tolerability, drug interactions, contraindications, and dosing regimens.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom